Diabetes drugs and weight loss - Mayo Clinic
Nov 14, 2024 · Benefits beyond weight loss. Along with helping to control blood sugar and boosting weight loss, GLP-1 agonists and SGLT-2 inhibitors seem to have other health benefits. Research has found that some of these medicines may lower the risk of certain serious health conditions, such as kidney disease, heart disease, heart failure and stroke.
Prescription weight-loss drugs: Can they help you? - Mayo Clinic
Oct 29, 2022 · Phentermine by itself (Adipex-P, Lomaira) also is used for weight loss. It's one of four similar weight-loss drugs approved for use for less than 12 weeks, called short-term use. The other drugs in this group aren't often prescribed. Semaglutide. Semaglutide also is used to help control type 2 diabetes. You take it as a weekly shot to manage ...
Semaglutide (subcutaneous route) - Mayo Clinic
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide injection is also used together with diet and exercise to help lose weight and keep the weight off in patients with at least one weight-related medical condition. This medicine is available only …
Use of weight-loss pharmacotherapy in patients with cirrhosis and …
Aug 17, 2021 · The four weight-loss medications currently approved by the FDA for treatment of obesity are orlistat, phentermine-topiramate, naltrexone-bupropion and liraglutide. Although some society guidelines have endorsed the use of these medications in patients with cirrhosis or in liver transplant recipients, they have not yet been widely used in this ...
Liraglutide (subcutaneous route) - Mayo Clinic
This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. Liraglutide injection is also used together with a reduced-calorie diet and proper exercise to help patients with obesity lose weight. This medicine is available only with your doctor's prescription.
ناهضات GLP-1: عقاقير مرض السكري وفقدان الوزن - Mayo Clinic (مايو كلينك)
Hu M, et al. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: A meta-analysis.
Alli weight-loss pill: Does it work? - Mayo Clinic
Apr 9, 2024 · A weight-loss plan with diet, exercise and drug therapy is generally considered successful if you lose about 1 pound (0.5 kilogram) a week during the first month. Losing 5% or more of the pre-treatment body weight within one year is also considered successful.
Management of obesity within hepatology clinics - Mayo Clinic
Dec 12, 2023 · Glucagon-like peptide 1 (GLP-1) receptor agonists. These agents can lead to significant weight loss. According to Dr. Watt, developing a solid understanding of how the various GLP-1 receptor agonists differ from one another may help clinicians choose the most appropriate agent for an individual patient. The Hepatology article contains a ...
Why gastroenterologists and hepatologists should be involved in ...
Jun 16, 2023 · GLP-1 agonists are associated with an increased risk of biliary tract and gallbladder diseases, so it's necessary to watch for adverse effects. A dual incretin agonist (GLP-1/glucose-dependent insulinotropic peptide) tirzepatide also is efficacious in treating obesity, improving glycemic control and reducing liver fat content.
Tirzepatide (subcutaneous route) - Mayo Clinic
It is used together with diet and exercise to help control your blood sugar. Tirzapatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certain conditions.